Sirtuin Modulators

Introduction

Sirtuin Modulators is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Sirtuins are NAD+-dependent deacetylases that regulate cellular metabolism, stress responses, and aging. Sirtuin modulators, particularly SIRT1 and SIRT2 inhibitors and activators, represent a promising therapeutic approach for neurodegenerative diseases by targeting mitochondrial function, oxidative stress, and protein aggregation. [@milne2007]

Overview

Sirtuin Biology

SIRT1

• Nuclear sirtuin involved in transcriptional regulation
• Deacetylates PGC-1α, FOXO, p53, [NF-κB](/entities/nf-kb)
• Promotes mitochondrial biogenesis
• Neuroprotective effects in AD and PD models

SIRT2

• Cytoplasmic and nuclear sirtuin
• Deacetylates α-tubulin, FOXO
• Regulates microtubule dynamics
• SIRT2 inhibition shows promise in PD

SIRT3

• Mitochondrial sirtuin
• Deacetylates SOD2, IDH2, PDH
• Regulates mitochondrial [ROS](/entities/reactive-oxygen-species)
• Protective in neurodegenerative models

Molecular Mechanism

SIRT1 Activation

Introduction

Sirtuin Modulators is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Sirtuins are NAD+-dependent deacetylases that regulate cellular metabolism, stress responses, and aging. Sirtuin modulators, particularly SIRT1 and SIRT2 inhibitors and activators, represent a promising therapeutic approach for neurodegenerative diseases by targeting mitochondrial function, oxidative stress, and protein aggregation. [@milne2007]

Overview

Sirtuin Biology

SIRT1

• Nuclear sirtuin involved in transcriptional regulation
• Deacetylates PGC-1α, FOXO, p53, [NF-κB](/entities/nf-kb)
• Promotes mitochondrial biogenesis
• Neuroprotective effects in AD and PD models

SIRT2

• Cytoplasmic and nuclear sirtuin
• Deacetylates α-tubulin, FOXO
• Regulates microtubule dynamics
• SIRT2 inhibition shows promise in PD

SIRT3

• Mitochondrial sirtuin
• Deacetylates SOD2, IDH2, PDH
• Regulates mitochondrial [ROS](/entities/reactive-oxygen-species)
• Protective in neurodegenerative models

Molecular Mechanism

SIRT1 Activation

SIRT1 activators work through:

Benefits:

• Enhanced mitochondrial biogenesis
• Reduced oxidative stress
• Improved neuronal survival
• Enhanced [autophagy](/entities/autophagy)

SIRT2 Inhibition

SIRT2 inhibitors:

• Reduce [α-synuclein](/proteins/alpha-synuclein) toxicity
• Protect dopaminergic [neurons](/entities/neurons)
• Improve motor function in PD models

Therapeutic Applications

Alzheimer's Disease

SIRT1 activation benefits:

• Reduced [amyloid-beta](/proteins/amyloid-beta) production
• Enhanced [tau](/proteins/tau) deacetylation
• Improved mitochondrial function
• Reduced neuroinflammation

• Reduced [Aβ](/proteins/amyloid-beta) pathology in [APP](/entities/app-protein)/PS1 mice
• Improved cognitive function
• Enhanced neuronal survival

Parkinson's Disease

SIRT2 inhibition benefits:

• Reduced α-synuclein aggregation
• Protection of dopaminergic neurons
• Improved motor function

Huntington's Disease

SIRT1 activation benefits:

• Enhanced mitochondrial function
• Reduced mutant [huntingtin](/proteins/huntingtin-protein) toxicity
• Improved neuronal survival

ALS

SIRT1 and SIRT3 activation:

• Enhanced mitochondrial function
• Reduced oxidative stress
• Improved motor neuron survival

Drug Candidates

| Compound | Target | Company | Stage | Mechanism |
|----------|--------|---------|-------|----------|
| Resveratrol | SIRT1 | Repurposed | Phase 2/3 | Direct SIRT1 activator |
| SRT2104 | SIRT1 | Sirtris | Phase 1 | SIRT1 selective activator |
| SRT3025 | SIRT1 | Sirtris | Preclinical | SIRT1 activator |
| AGK2 | SIRT2 | Preclinical | N/A | SIRT2 inhibitor |
| EX-527 | SIRT2 | Preclinical | N/A | SIRT2 inhibitor |
| NAD+ precursors | SIRT1/3 | Various | Phase 2 | NAD+ boosting |

Clinical Trials

• NCT00644189: Resveratrol for Alzheimer's disease (completed)
• NCT03718893: Resveratrol for Parkinson's disease (completed)
• NCT03061812: NAD+ precursors for Parkinson's disease (completed)

Challenges and Limitations

Future Directions

• Development of brain-penetrant SIRT1 activators
• Selective SIRT2 inhibitors for PD
• Combination with NAD+ boosters
• Gene therapy approaches

See Also

• [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway)
• [Oxidative Stress Pathway](/mechanisms/oxidative-stress-pathway)
• [NAD+ Metabolism](/mechanisms/nad-metabolism)
• [PGC-1α Signaling](/mechanisms/pgc1-alpha-signaling)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

Background

The study of Sirtuin Modulators has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK1/Parkin Mitophagy Dysfunction](/hypothesis/h-seaad-v4-5a7a4079) — <span style="color:#81c784;font-weight:600">0.62</span> · Target: SIRT3
• [Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancement](/hypothesis/h-57862f8a) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: IDH2
• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Stress Granule Phase Separation Modulators](/hypothesis/h-97aa8486) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: G3BP1
• [Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration](/hypothesis/h-0e614ae4) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: SIRT3
• [Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators](/hypothesis/h-ba3a948a) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: CX3CR1
• [Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancement](/hypothesis/h-57862f8a) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: IDH2

Related Analyses:

• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;
• [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) &#x1f504;
• [Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v4-20260402065846) &#x1f504;